Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hans Hasselbalch is active.

Publication


Featured researches published by Hans Hasselbalch.


Expert Opinion on Biological Therapy | 2007

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family

Claus Henrik Nielsen; Daniel El Fassi; Hans Hasselbalch; Klaus Bendtzen; Laszlo Hegedüs

In this review, the authors summarise the clinical results obtained after therapy with rituximab in autoimmune dieases, including Graves’ disease and Graves’ ophthalmopathy. On the basis of qualitative and quantitative analyses of B- and T-cell subsets, and autoantibody levels obtained in other diseases before and after rituximab therapy, the authors interpret the results of the only two clinical investigtions of the efficacy of rituximab in the treatment of Graves’ disease and Graves’ opthalmopathy reported so far. No significant effect on autoantibody levels was observed. Nonetheless, 4 out of 10 Graves’ disease patients remained in remission 400 days after rituximab treatment versus none in the control group, and remarkable improvements in the eye symptoms of patients with Graves’ ophthalmopathy were observed. This supports a role for B cells in the pathogenesis of Graves’ ophthalmopathy, and the authors suggest that abrogation of antigen presentation by B cells accounts for the effect of rituximab. In the authors’ opinion, the use of rituximab in severe Graves’ ophthalmopathy could be contemplated.


Cancer Genetics and Cytogenetics | 1991

Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia

Preben Philip; Christian H. Geisler; Mogens Mørk Hansen; Hans Hasselbalch; Bjarne Egelund Christensen; Aage Drivsholm; Birgit Villadsen Lund; Jørgen Boye Nielsen; Kaj Bjørn Jensen; Erik Andersen

Aberrations of chromosome 6 were observed in 11 of 193 cases of chronic lymphocytic leukemia diagnosed January 1, 1984-November 1, 1988 and investigated cytogenetically within 30 days after diagnosis. The 6p was rearranged in 5 cases: 4 balanced and 1 unbalanced translocation. The 6q was involved in 6 cases: 4 deletions and 2 balanced translocations. Three of the del(6q) may be identical: del(6)(q13q27). In two cases there were no additional aberrations. Aberrations of chromosome 6 correlated significantly with an advanced clinical stage, diffuse pattern of bone marrow infiltration, and increased SmIgM-fluorescence intensity. All these factors are associated with poor prognosis. Although the number of cases with 6q aberrations is still too small and the observation period too short to show significant influence on survival, the presence of 6q aberrations at diagnosis may prove useful in delineating a subtype of chronic lymphocytic leukemia with poor prognosis.


American Journal of Hematology | 2005

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Treatment for Adult Refractory Idiopathic Thrombocytopenic Purpura

Peter Brændstrup; Ole Weis Bjerrum; Ove Juul Nielsen; Bjarne Anker Jensen; Nielsaage Tøffner Clausen; Per Boye Hansen; Ivan Andersen; Kai Gjerløff Schmidt; Torben Mourits Andersen; Niels Anker Peterslund; Henrik Birgens; Torben Plesner; Bjarne Bach Pedersen; Hans Hasselbalch


The Journal of Clinical Endocrinology and Metabolism | 2007

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Daniel El Fassi; Claus Henrik Nielsen; Steen Joop Bonnema; Hans Hasselbalch; Laszlo Hegedüs


Annals of Hematology | 2008

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera

Thomas Stauffer Larsen; Ole Weis Bjerrum; Niels Pallisgaard; M. T. Andersen; Michael Boe Møller; Hans Hasselbalch


Clinical and Laboratory Haematology | 2004

Anagrelide treatment in 52 patients with chronic myeloproliferative diseases

E. Penninga; B. A. Jensen; P. B. Hansen; N. T. Clausen; T. Mourits-Andersen; O. J. Nielsen; Hans Hasselbalch


Cancer Genetics and Cytogenetics | 2007

A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis

Thomas Stauffer Larsen; Hans Hasselbalch; Niels Pallisgaard; Gitte Kerndrup


Journal of Blood Research & Hematologic Diseases | 2016

Autoimmune Thyroid Disease in Patients with Philadelphia-Negative ChronicMyeloproliferative Neoplasms Treated with Interferon-Alpha

Cecilie Paulsrud; Hans Hasselbalch; Ole Weis Bjerrum


Archive | 2013

Whole Blood Transcriptional Profi ling Reveals Signifi cant Downregulation of HLA Class I and II Genes in Essential Thrombocythemia, Polycythemia Vera and Myelofi brosis

Vibe Skov; Caroline Hasselbalch Riley; Mads Thomassen; Thomas Stauffer Larsen; Morten Krogh Jensen; Ole Weis Bjerrum; Torben A. Kruse; Hans Hasselbalch


Blood | 2004

Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.

Hans Hasselbalch

Collaboration


Dive into the Hans Hasselbalch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel El Fassi

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Laszlo Hegedüs

Odense University Hospital

View shared research outputs
Top Co-Authors

Avatar

Niels Pallisgaard

Odense University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bjarne Anker Jensen

Copenhagen University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge